ResMed Inc. (NYSE:RMD) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 52.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,692 shares of the medical equipment provider’s stock after acquiring an additional 15,345 shares during the quarter. Pacer Advisors Inc.’s holdings in ResMed were worth $10,221,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. True Wealth Design LLC raised its holdings in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of ResMed in the third quarter worth $34,000. Rosenberg Matthew Hamilton bought a new stake in shares of ResMed during the fourth quarter valued at about $54,000. Capital Performance Advisors LLP acquired a new stake in ResMed in the third quarter worth about $60,000. Finally, Quarry LP grew its position in ResMed by 271.9% in the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 242 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the sale, the director now owns 83,204 shares of the company’s stock, valued at approximately $20,696,162.96. This represents a 2.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Justin Leong sold 6,160 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the transaction, the insider now owns 21,718 shares in the company, valued at approximately $5,279,428.62. The trade was a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,099 shares of company stock valued at $2,719,385. 0.71% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Stifel Nicolaus initiated coverage on ResMed in a research report on Friday, December 13th. They issued a “hold” rating and a $250.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Royal Bank of Canada lifted their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Piper Sandler assumed coverage on shares of ResMed in a report on Friday, January 10th. They issued a “neutral” rating and a $252.00 price target for the company. Finally, KeyCorp upped their price target on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus price target of $238.40.

ResMed Stock Down 1.8 %

NYSE:RMD opened at $250.03 on Wednesday. ResMed Inc. has a 1 year low of $170.56 and a 1 year high of $260.49. The stock has a 50-day moving average price of $239.56 and a two-hundred day moving average price of $235.40. The stock has a market cap of $36.70 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 1.78 and a beta of 0.70. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.